Basic mechanisms underlying prenylamine-induced ‘torsade de pointes’: differences between prenylamine and fendiline due to basic actions of the isomers

References

• Abinader E. G., Shahar J. Possible female preponderance in prenylamine-induced ‘Torsade de pointes’ tachycardia. Cardiology 1983; 70: 37–401. Abinader E. G., Shahar J. Possible female preponderance in prenylamine-induced ‘Torsade de pointes’ tachycardia. Cardiology 1983; 70: 37–40
   PubMed Web of Science ®Google Scholar
• Bayer R., Ehara T. Comparative studies on calcium antagonists. Progr. Pharmacol. 1978; 2: 31–372. Bayer R., Ehara T. Comparative studies on calcium antagonists. Progr. Pharmacol. 1978; 2: 31–37
   Google Scholar
• Bayer R., Hennekes R., Kaufmann R., Mannhold R. Inotropic and electro-physiological actions of verapamil and D 600 in mammalian myocardium. I. Pattern of inotropic effects of the racemic compounds. Naunyn Schmiedeberg's Arch. Pharmacol. 1975; 290: 49–683. Bayer R., Hennekes R., Kaufmann R., Mannhold R. Inotropic and electro-physiological actions of verapamil and D 600 in mammalian myocardium. I. Pattern of inotropic effects of the racemic compounds. Naunyn Schmiedeberg's Arch. Pharmacol. 1975; 290: 49–68
   Google Scholar
• Bayer R., Kalusche D., Kaufmann R., Mannhold R. Inotropic and electro-physiological actions of verapamil and D 600 in mammalian myocardium. III. Effects of the optical isomers on transmembrane action potentials. Naunyn Schmiedeberg's Arch. Pharmacol. 1975; 290: 81–974. Bayer R., Kalusche D., Kaufmann R., Mannhold R. Inotropic and electro-physiological actions of verapamil and D 600 in mammalian myocardium. III. Effects of the optical isomers on transmembrane action potentials. Naunyn Schmiedeberg's Arch. Pharmacol. 1975; 290: 81–97
   Google Scholar
• Bayer R., Kaufmann R., Mannhold R. Inotropic and electrophysiological actions of verapamil and D 600 in mammalian myocardium. II. Pattern of inotropic effects of the optical isomers. Naunyn Schmiedeberg's Arch. Pharmacol. 1975; 290: 69–805. Bayer R., Kaufmann R., Mannhold R. Inotropic and electrophysiological actions of verapamil and D 600 in mammalian myocardium. II. Pattern of inotropic effects of the optical isomers. Naunyn Schmiedeberg's Arch. Pharmacol. 1975; 290: 69–80
   Google Scholar
• Bayer R., Kaufmann R., Mannhold R., Rodenkirchen R. IV. The action of specific Ca antagonists on cardiac electrical activity. Progr. Pharmacol. 1982; 5: 53–856. Bayer R., Kaufmann R., Mannhold R., Rodenkirchen R. IV. The action of specific Ca antagonists on cardiac electrical activity. Progr. Pharmacol. 1982; 5: 53–85
   Google Scholar
• Bayer R., Mannhold R. Fendiline: a review of its basic pharmacological and clinical properties. Pharmatherapeutica 1987; 5: 103–1367. Bayer R., Mannhold R. Fendiline: a review of its basic pharmacological and clinical properties. Pharmatherapeutica 1987; 5: 103–136
   PubMedGoogle Scholar
• Bayer R., Martini E., Heckelmann F. Calcium channel independent action of fendiline in vascular smooth muscle. J. Mol. Cell. Cardiol. 1987; 19: 12, Suppl. III8. Bayer R., Martini E., Heckelmann F. Calcium channel independent action of fendiline in vascular smooth muscle. J. Mol. Cell. Cardiol. 1987; 19: 12, Suppl. III
   Google Scholar
• Bayer R., Rodenkirchen R., Ehara T., Mannhold R. Comparative studies of inotropic and electrophysiological effects of ‘slow channel inhibitors’ in isolated mammalian cardiac muscle. Naunyn Schmiedeberg's Arch. Pharmacol. 1976; 301: 29–379. Bayer R., Rodenkirchen R., Ehara T., Mannhold R. Comparative studies of inotropic and electrophysiological effects of ‘slow channel inhibitors’ in isolated mammalian cardiac muscle. Naunyn Schmiedeberg's Arch. Pharmacol. 1976; 301: 29–37
   Google Scholar
• Belz G. G. Fendiline: clinical pharmacological profile of a Ca2+-antagonist. J. Mol. Cell. Cardiol. 1987; 19: 13, Suppl. III10. Belz G. G. Fendiline: clinical pharmacological profile of a Ca2+-antagonist. J. Mol. Cell. Cardiol. 1987; 19: 13, Suppl. III
   PubMedGoogle Scholar
• Busse R. Die Kontraktion der glatten Gefäŝmuskulatur und ihre Beeinfluŝbarkeit durch Calmodulinantagonisten. Drug Development and Evaluation, E. LÜThy. G. Fischer Verlag, Stuttgart, New York 1985; 11: 55–7011. Busse R. Die Kontraktion der glatten Gefäŝmuskulatur und ihre Beeinfluŝbarkeit durch Calmodulinantagonisten. Drug Development and Evaluation, E. LÜThy. G. Fischer Verlag, Stuttgart, New York 1985; 11: 55–70
   Google Scholar
• Craig T. J., Riddle J. M. Early after depolarization and Ca++. Circulation 1987; 76, Suppl. II, Abstr. No. 188412. Craig T. J., Riddle J. M. Early after depolarization and Ca++. Circulation 1987; 76, Suppl. II, Abstr. No. 1884
   Google Scholar
• Demiroglu C., Berkarda B., Garan R. Behandlung von Herzrhythmusstörungen mit Segontin. Münch. Med. Wochenschr. 1987; 107: 255813. Demiroglu C., Berkarda B., Garan R. Behandlung von Herzrhythmusstörungen mit Segontin. Münch. Med. Wochenschr. 1987; 107: 2558
   Google Scholar
• Ehara T., Kaufmann R. The voltage- and time-dependent effects of (—)-verapamil on the slow inward current in isolated cat ventricular myocardium. J. Pharmacol. Exp. Ther. 1978; 207: 49–5514. Ehara T., Kaufmann R. The voltage- and time-dependent effects of (—)-verapamil on the slow inward current in isolated cat ventricular myocardium. J. Pharmacol. Exp. Ther. 1978; 207: 49–55
   PubMed Web of Science ®Google Scholar
• Ferry D., Glossmann H. Evidence for multiple receptor sites within the putative calcium channel. Naunyn Schmiedeberg's Arch. Pharmacol. 1982; 321: 80–8315. Ferry D., Glossmann H. Evidence for multiple receptor sites within the putative calcium channel. Naunyn Schmiedeberg's Arch. Pharmacol. 1982; 321: 80–83
   Google Scholar
• Fleckenstein A. Pharmacology and electrophysiology of calcium antagonists. Calcium Antagonism in Cardiovascular Therapy: Experience with Verapamil. Excerpta Medica, Amsterdam, Oxford, Princeton 1981; 10–2916. Fleckenstein A. Pharmacology and electrophysiology of calcium antagonists. Calcium Antagonism in Cardiovascular Therapy: Experience with Verapamil. Excerpta Medica, Amsterdam, Oxford, Princeton 1981; 10–29
   Google Scholar
• Fleckenstein A., Fleckenstein-GrÜN G., Byon Y. K. Fundamentale Herz- und Gefäŝwirkungen des Ca-antagonistischen Koronartherapeutikums Fendilin (Sensit). Drug Res. 1977; 27: 562–57117. Fleckenstein A., Fleckenstein-GrÜN G., Byon Y. K. Fundamentale Herz- und Gefäŝwirkungen des Ca-antagonistischen Koronartherapeutikums Fendilin (Sensit). Drug Res. 1977; 27: 562–571
   Google Scholar
• Fleckenstein A., Kammermeier H., DÖRing H. J., Freund H. J. Zum Wirkungs-mechanismus neuartiger Koronardilatatoren mit gleichzeitig Sauerstoff-einsparenden Myokard-Effekten, Prenylamin und Iproveratril. Zeitschr. Kreislaufforsch. 1967; 56: 716–744; 839–85618. Fleckenstein A., Kammermeier H., DÖRing H. J., Freund H. J. Zum Wirkungs-mechanismus neuartiger Koronardilatatoren mit gleichzeitig Sauerstoff-einsparenden Myokard-Effekten, Prenylamin und Iproveratril. Zeitschr. Kreislaufforsch. 1967; 56: 716–744; 839–856
   PubMedGoogle Scholar
• Fraser A. G., Ikram S. Torsade de point with prenylamine: Do we still need the drug?. Lancet 1986; 2: 57219. Fraser A. G., Ikram S. Torsade de point with prenylamine: Do we still need the drug?. Lancet 1986; 2: 572
   PubMed Web of Science ®Google Scholar
• Glossmann H., Ferry D., Goll A., Rombusch M. Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, (125)Iodipine. J. Cardiovasc. Pharmacol. 1984; 6: S608–S62120. Glossmann H., Ferry D., Goll A., Rombusch M. Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, (125)Iodipine. J. Cardiovasc. Pharmacol. 1984; 6: S608–S621
   PubMed Web of Science ®Google Scholar
• Glossmann H., Ferry D., LÜBbecke F., Mewes R., Hofmann F. Calcium channels: direct identification with radioligand binding studies. T.I.P.S. 1982; 3: 431–43721. Glossmann H., Ferry D., LÜBbecke F., Mewes R., Hofmann F. Calcium channels: direct identification with radioligand binding studies. T.I.P.S. 1982; 3: 431–437
   Web of Science ®Google Scholar
• Glossmann H., Ferry D., LÜBbecke F., Mewes R., Hofmann F. Identification of voltage operated calcium channels by binding studies: differentiation of subclasses of calcium antagonist drugs with (3H)-nimodipine radioligand binding. J. Receptor Res. 1983; 3: 177–19022. Glossmann H., Ferry D., LÜBbecke F., Mewes R., Hofmann F. Identification of voltage operated calcium channels by binding studies: differentiation of subclasses of calcium antagonist drugs with (3H)-nimodipine radioligand binding. J. Receptor Res. 1983; 3: 177–190
   PubMed Web of Science ®Google Scholar
• Grenadier E., Keider S., Alpan G., Marmor A., Palant A. Prenylamine induced ventricular tachycardia and syncope controlled by ventricular pacing. Br. Heart J. 1980; 44: 330–33423. Grenadier E., Keider S., Alpan G., Marmor A., Palant A. Prenylamine induced ventricular tachycardia and syncope controlled by ventricular pacing. Br. Heart J. 1980; 44: 330–334
   PubMedGoogle Scholar
• Haas H. G., Kern R., Benninger C., EinwÄChter H. M. Effects of prenylamine on cardiac membrane currents and contractility. J. Pharmacol. Exp. Ther. 1975; 192: 688–70124. Haas H. G., Kern R., Benninger C., EinwÄChter H. M. Effects of prenylamine on cardiac membrane currents and contractility. J. Pharmacol. Exp. Ther. 1975; 192: 688–701
   PubMed Web of Science ®Google Scholar
• Hashimoto K., Nakagawa Y., Nabata H., Imai S. In vitro analysis of Ca-antagonistic effects of prenylamine as mechanisms for its cardiac actions. Arch. Int. Pharmacodyn. Ther. 1978; 273: 212–22125. Hashimoto K., Nakagawa Y., Nabata H., Imai S. In vitro analysis of Ca-antagonistic effects of prenylamine as mechanisms for its cardiac actions. Arch. Int. Pharmacodyn. Ther. 1978; 273: 212–221
   Google Scholar
• Henry P. D. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am. J. Cardiol. 1980; 46: 1047–105826. Henry P. D. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am. J. Cardiol. 1980; 46: 1047–1058
   PubMed Web of Science ®Google Scholar
• Johnson J. D., Vaghy P. L., Crouch T. H., Potter J. D., Schwartz A. An hypothesis for the mechanism of action of some of the Ca-antagonist drugs: calmodulin as a receptor. Adv. Pharmacol. Ther. 1982; 3: 121–13827. Johnson J. D., Vaghy P. L., Crouch T. H., Potter J. D., Schwartz A. An hypothesis for the mechanism of action of some of the Ca-antagonist drugs: calmodulin as a receptor. Adv. Pharmacol. Ther. 1982; 3: 121–138
   Google Scholar
• Kazda S., Knorr A., Towart R. Common properties and differences between various calcium antagonists. Progr. Pharmacol. 1983; 5: 83–11628. Kazda S., Knorr A., Towart R. Common properties and differences between various calcium antagonists. Progr. Pharmacol. 1983; 5: 83–116
   Google Scholar
• Kecskemeti V., Kelemen K., Knoll J. Effect of verapamil and D 600 on cardiac transmembrane potentials. Acta Physiol. Acad. Sci. Hung. 1978; 51: 51–5929. Kecskemeti V., Kelemen K., Knoll J. Effect of verapamil and D 600 on cardiac transmembrane potentials. Acta Physiol. Acad. Sci. Hung. 1978; 51: 51–59
   PubMedGoogle Scholar
• Kukovetz W. R., PÖCh G., Holzmann S., Paietta E. Wirkung von Fendilin auf Herz und glatte Muskulatur. Drug Res. 1976; 26: 1321–133030. Kukovetz W. R., PÖCh G., Holzmann S., Paietta E. Wirkung von Fendilin auf Herz und glatte Muskulatur. Drug Res. 1976; 26: 1321–1330
   Google Scholar
• Lindner E., Kaiser J. Die antiarrhythmische Wirkung des Segontin (3-Phenylpropyl-[2])-1,1-diphenyl-propyl-(3) amins. Herz Kreisl. 1975; 7: 88–9431. Lindner E., Kaiser J. Die antiarrhythmische Wirkung des Segontin (3-Phenylpropyl-[2])-1,1-diphenyl-propyl-(3) amins. Herz Kreisl. 1975; 7: 88–94
   Google Scholar
• Mannhold R. Kalziumantagonisten vom Typ der aliphatischen Amine und strukturverwandte herzaktive Pharmaka. Verlag Dr. P. Mannhold, Gelsenkirchen 198332. Mannhold R. Kalziumantagonisten vom Typ der aliphatischen Amine und strukturverwandte herzaktive Pharmaka. Verlag Dr. P. Mannhold, Gelsenkirchen 1983
   Google Scholar
• Mannhold R., Kramer A., SchÄFer W., Schramm P. CaM-inhibitory actions of Ca antagonists. Arch. Pharm. (Weinheim) 1987; 320: 683–69233. Mannhold R., Kramer A., SchÄFer W., Schramm P. CaM-inhibitory actions of Ca antagonists. Arch. Pharm. (Weinheim) 1987; 320: 683–692
   PubMed Web of Science ®Google Scholar
• Mannhold R., Rodenkirchen R., Bayer R. III. Qualitative and quantitative structure-activity relationships of specific Ca antagonists. Progr. Pharmacol. 1982; 5: 25–5234. Mannhold R., Rodenkirchen R., Bayer R. III. Qualitative and quantitative structure-activity relationships of specific Ca antagonists. Progr. Pharmacol. 1982; 5: 25–52
   Google Scholar
• Meanock C. J., Noble M. I. M. A case of prenylamine toxicity showing torsade de pointes phenomenon in sinus rhythm?. Postgrad. Med. J. 1981; 57: 381–38435. Meanock C. J., Noble M. I. M. A case of prenylamine toxicity showing torsade de pointes phenomenon in sinus rhythm?. Postgrad. Med. J. 1981; 57: 381–384
   PubMed Web of Science ®Google Scholar
• Mouille P., Cheymol G., Duteil J. Cardiovascular and antiarrhythmic effects of fendiline compared to prenylamine in the dog. Drug Res. 1977; 27: 1954–195836. Mouille P., Cheymol G., Duteil J. Cardiovascular and antiarrhythmic effects of fendiline compared to prenylamine in the dog. Drug Res. 1977; 27: 1954–1958
   Web of Science ®Google Scholar
• Nabata H. Effects of calcium-antagonistic coronary vasodilators on myocardial contractility and membrane potentials. Jpn. J. Pharmacol. 1977; 27: 239–24937. Nabata H. Effects of calcium-antagonistic coronary vasodilators on myocardial contractility and membrane potentials. Jpn. J. Pharmacol. 1977; 27: 239–249
   PubMedGoogle Scholar
• Nakajiama H., Hoshiyama M., Yamashita K., Kiyomoto A. Effect of diltiazem on electrical and mechanical activity of isolated cardiac ventricular muscle of guinea pig. Jpn. J. Pharmacol. 1975; 25: 383–39238. Nakajiama H., Hoshiyama M., Yamashita K., Kiyomoto A. Effect of diltiazem on electrical and mechanical activity of isolated cardiac ventricular muscle of guinea pig. Jpn. J. Pharmacol. 1975; 25: 383–392
   PubMedGoogle Scholar
• Nielsen K. C., Owman C. Control of ventricular fibrillation during induced hypothermia in cats after differential depletion of cardiac catecholamine stores with prenylamine (Segontin). Circ. Res. 1967; 21: 45–5839. Nielsen K. C., Owman C. Control of ventricular fibrillation during induced hypothermia in cats after differential depletion of cardiac catecholamine stores with prenylamine (Segontin). Circ. Res. 1967; 21: 45–58
   PubMed Web of Science ®Google Scholar
• Normand J. P., Kahn J. C., Mialet A. Torsades de pointes induites ou à favorisées par la prénylamine. A propis de 4 observations. Ann. Cardiol Angiol. 1974; 23: 527–53340. Normand J. P., Kahn J. C., Mialet A. Torsades de pointes induites ou à favorisées par la prénylamine. A propis de 4 observations. Ann. Cardiol Angiol. 1974; 23: 527–533
   PubMedGoogle Scholar
• Oakley D., Jennings K., Puritz R., Krikler D., Chamberlain D. The effect of prenylamine of the QT interval of the resting electrocardiogram in patients with angina pectoris. Postgrad. Med. J. 1980; 56: 753–75641. Oakley D., Jennings K., Puritz R., Krikler D., Chamberlain D. The effect of prenylamine of the QT interval of the resting electrocardiogram in patients with angina pectoris. Postgrad. Med. J. 1980; 56: 753–756
   PubMed Web of Science ®Google Scholar
• Pott L., Lipp P. Dual effects of the Ca2+ calmodulin antagonist fendiline on Ca current in single cardiac cells. J. Mol. Cell. Cardiol. 1987; 19: 225, Suppl. III42. Pott L., Lipp P. Dual effects of the Ca2+ calmodulin antagonist fendiline on Ca current in single cardiac cells. J. Mol. Cell. Cardiol. 1987; 19: 225, Suppl. III
   Google Scholar
• Puritz R., Henderson M. A., Baker S. N., Chamberlain D. A. Ventricular arrhythmias caused by prenylamine. Br. Med. J. 1987; 2: 608–60943. Puritz R., Henderson M. A., Baker S. N., Chamberlain D. A. Ventricular arrhythmias caused by prenylamine. Br. Med. J. 1987; 2: 608–609
   Google Scholar
• Quiret J. C., Bens J. L., Courbet M. T., Lesbre J. P., Bernasconi P. Les torsades de pointes: un modèle de pathologic iatrogène. Ann. Med. Interne (Paris) 1976; 127: 61544. Quiret J. C., Bens J. L., Courbet M. T., Lesbre J. P., Bernasconi P. Les torsades de pointes: un modèle de pathologic iatrogène. Ann. Med. Interne (Paris) 1976; 127: 615
   PubMedGoogle Scholar
• Riccioni N., Bartolomei C., Soldani S. Prenylamine-induced ventricular arrhythmias and syncopal attacks with Q-T prolongation. Cardiology 1980; 66: 199–20345. Riccioni N., Bartolomei C., Soldani S. Prenylamine-induced ventricular arrhythmias and syncopal attacks with Q-T prolongation. Cardiology 1980; 66: 199–203
   PubMed Web of Science ®Google Scholar
• Rodenkirchen R., Bayer R., Mannhold R. II. Specific and non specific Ca antagonists. A structure-activity analysis of cardiodepressive drugs. Progr. Pharmacol. 1982; 5: 9–2346. Rodenkirchen R., Bayer R., Mannhold R. II. Specific and non specific Ca antagonists. A structure-activity analysis of cardiodepressive drugs. Progr. Pharmacol. 1982; 5: 9–23
   Google Scholar
• Rosen M. R., Wit A. L., Hoffman B. F. Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. Am. Herat J. 1975; 89: 665–67347. Rosen M. R., Wit A. L., Hoffman B. F. Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. Am. Herat J. 1975; 89: 665–673
   PubMed Web of Science ®Google Scholar
• RÜEgg J. C., Pfitzer G. Calcium-Calmodulin-antagonistischen Wirkungen von Fendilin an der glatten Muskulatur. Drug Development and Evaluation, E. Luthy. G. Fischer Verlag, Stuttgart, New York 1985; 11: 33–4048. RÜEgg J. C., Pfitzer G. Calcium-Calmodulin-antagonistischen Wirkungen von Fendilin an der glatten Muskulatur. Drug Development and Evaluation, E. Luthy. G. Fischer Verlag, Stuttgart, New York 1985; 11: 33–40
   Google Scholar
• Saikawa R., Nagamoto Y., Arita M. Electrophysiological effects of diltiazem, a new slow channel inhibitor, on canine cardiac fibres. Jpn. Heart J. 1977; 18: 235–24549. Saikawa R., Nagamoto Y., Arita M. Electrophysiological effects of diltiazem, a new slow channel inhibitor, on canine cardiac fibres. Jpn. Heart J. 1977; 18: 235–245
   PubMedGoogle Scholar
• SchÖNe H. H., Lindner E. Die Wirkung des N-(3-phenyl-propyl-(2)-1,1-diphenyl-propyl-(3)amin auf den Katecholaminstoffwechsel. Klin. Wochenschr. 1962; 40: 119650. SchÖNe H. H., Lindner E. Die Wirkung des N-(3-phenyl-propyl-(2)-1,1-diphenyl-propyl-(3)amin auf den Katecholaminstoffwechsel. Klin. Wochenschr. 1962; 40: 1196
   Google Scholar
• SpÄH F., Fleckenstein A. Nachweis einer strengen Korrelation zwischen Hemmung des transmebranären Calcium-Influx und der mechanischen Spannungsentwicklung des Myokards unter dem Einfluŝ verschiedener Calcium-Antagonisten. Calcium-Antagonismus, A. Fleckenstein, H. Roskamm. Springer Verlag, Berlin, Heidelberg, New York 1980; 29–4151. SpÄH F., Fleckenstein A. Nachweis einer strengen Korrelation zwischen Hemmung des transmebranären Calcium-Influx und der mechanischen Spannungsentwicklung des Myokards unter dem Einfluŝ verschiedener Calcium-Antagonisten. Calcium-Antagonismus, A. Fleckenstein, H. Roskamm. Springer Verlag, Berlin, Heidelberg, New York 1980; 29–41
   Google Scholar
• SpÄTh G. Torsade de pointes, G. SpÄTh. Ueberreuter Wissenschaft, Wien 1988; 102–10452. SpÄTh G. Torsade de pointes, G. SpÄTh. Ueberreuter Wissenschaft, Wien 1988; 102–104
   Google Scholar
• Spedding M. Assessment of ‘Ca-antagonist’ effects of drugs in K-depolarized smooth muscle. Naunyn Schmiedeberg's Arch. Pharmacol. 1982; 318: 234–24053. Spedding M. Assessment of ‘Ca-antagonist’ effects of drugs in K-depolarized smooth muscle. Naunyn Schmiedeberg's Arch. Pharmacol. 1982; 318: 234–240
   Google Scholar
• Spedding M. Direct inhibitory effects of some ‘calcium antagonists’ and trifluoperazine on the contractile proteins in smooth muscle. Br. J. Pharmacol. 1983; 79: 225–23154. Spedding M. Direct inhibitory effects of some ‘calcium antagonists’ and trifluoperazine on the contractile proteins in smooth muscle. Br. J. Pharmacol. 1983; 79: 225–231
   PubMed Web of Science ®Google Scholar
• Spedding M., Berg C. Interactions between a differentiate calcium antagonist subgroups in K-depolarized smooth muscle. Naunyn Schmiedeberg's Arch. Pharmacol. 1984; 328: 69–7555. Spedding M., Berg C. Interactions between a differentiate calcium antagonist subgroups in K-depolarized smooth muscle. Naunyn Schmiedeberg's Arch. Pharmacol. 1984; 328: 69–75
   Google Scholar
• SprÜGel W., Mitznegg P., Heim F. Der Einfluŝ des Ca-Antagonisten Fendilin auf Tonus und Motilität der glatten Darmmuskulatur des Meerschweinchens und auf die Konzentration von cAMP und cGMP im isolierten Ileum. Drug Res. 1977; 27: 571–57456. SprÜGel W., Mitznegg P., Heim F. Der Einfluŝ des Ca-Antagonisten Fendilin auf Tonus und Motilität der glatten Darmmuskulatur des Meerschweinchens und auf die Konzentration von cAMP und cGMP im isolierten Ileum. Drug Res. 1977; 27: 571–574
   Google Scholar
• Tritthart H. A., Koidl B. Das pharmakologische Wirkungsprinzip von Calciumantagonisten: Fendilin im Vergleich zu Nifedipin, Verapamil und Diltiazem. Drug Development and Evaluation, E. LÜThy. G. Fischer Verlag, Stuttgart, New York 1985; 11: 41–5357. Tritthart H. A., Koidl B. Das pharmakologische Wirkungsprinzip von Calciumantagonisten: Fendilin im Vergleich zu Nifedipin, Verapamil und Diltiazem. Drug Development and Evaluation, E. LÜThy. G. Fischer Verlag, Stuttgart, New York 1985; 11: 41–53
   Google Scholar
• Vanhoutte P. M., Paoletti R. The WHO classification of calcium antagonists. T.I.P.S. 1987; 8: 4–5558. Vanhoutte P. M., Paoletti R. The WHO classification of calcium antagonists. T.I.P.S. 1987; 8: 4–55
   Web of Science ®Google Scholar
• Zimmer M. Wechselwirkung zwischen Calmodulin, Myosinkinase und Calmodulin-“Antagonisten”. Thesis, University of Heidelberg. 198559. Zimmer M. Wechselwirkung zwischen Calmodulin, Myosinkinase und Calmodulin-“Antagonisten”. Thesis, University of Heidelberg. 1985
   Google Scholar
• Zimmer M., Hofmann F. ‘Calmodulin-antagonists’ (CaM-A) reveal differences in the interaction of calmodulin (CaM) with myosin light chain kinase (MLCK) and phospho-diesterase. Naunyn Schmiedeberg's Arch. Pharmacol. 1985; 329, Suppl., R160. Zimmer M., Hofmann F. ‘Calmodulin-antagonists’ (CaM-A) reveal differences in the interaction of calmodulin (CaM) with myosin light chain kinase (MLCK) and phospho-diesterase. Naunyn Schmiedeberg's Arch. Pharmacol. 1985; 329, Suppl., R1
   Google Scholar